Prestige Consumer Healthcare Inc. saw its shares fall over 11% on May 14, 2026, after the company revealed significant revenue declines and production problems driving its disappointing Q4 2026 financial results. The drop was triggered by a 5% year-over-year revenue decline and a 6.4% sequential decrease, with notable weakness in its North America OTC Eye & Ear Care and International OTC segments. The company's Clear Eyes® brand, a major product line, faced supply chain constraints due to issues at its recently acquired Pillar5 facility.

Investigation Launched

National shareholder rights firm Hagens Berman has opened an investigation into whether Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints before May 14, 2026. The firm is examining whether the company violated federal securities laws by failing to disclose the extent of the Pillar5 facility's performance issues. Reed Kathrein, the Hagens Berman partner leading the investigation, stated the focus is on when Prestige and its management first became aware of the facility's underperformance and whether investors were misled about progress in resolving Clear Eyes® supply issues.

Financial Performance Breakdown

The Q4 2026 results highlighted significant declines across key segments:

During the earnings call on May 14, 2026, management attributed the declines to "Clear Eyes supply constraints" and unexpected shutdowns at the Pillar5 facility. The company had previously touted the facility as a solution to persistent supply chain issues and a means to restore Clear Eyes® to its leading market share position.

Market Reaction

The market reacted swiftly to the news, sending Prestige shares significantly lower. Hagens Berman is encouraging investors who suffered substantial losses to submit their claims for potential recovery. The firm is also seeking whistleblowers with non-public information about Prestige's practices to assist in the investigation or participate in the SEC Whistleblower program, which offers rewards of up to 30% of successful SEC recoveries.

Prestige Consumer Healthcare Inc has finalized the acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion. The deal, closed on June 15, 2026, was executed under the terms of an asset purchase agreement initially announced on March 20, 2026. The acquisition represents a strategic expansion for Prestige into the nasal strip category, with Breathe Right becoming the company's largest brand.

The transaction value includes approximately $900 million net of anticipated tax benefits valued at $150 million. Breathe Right, established in the 1990s, is recognized as the number one brand in the nasal strip category. Prestige financed the acquisition using a combination of available cash on hand and a completed financing for a new Term Loan B.

Transaction Details

The acquisition was structured as an asset purchase agreement. The following table outlines the financial components of the deal:

Strategic Impact

The addition of Breathe Right diversifies Prestige Consumer Healthcare's portfolio, which already includes brands such as Monistat, BC, and Clear Eyes. The company markets, sells, manufactures, and distributes consumer healthcare products across the U.S., Canada, Australia, and other international markets. This move is expected to strengthen Prestige's position in the over-the-counter healthcare sector.